Bachert C, Brostoff J, Scadding G K, Tasman J, Stalla-Bourdillon A, Murrieta M
ENT Department, University of Ghent, Belgium.
Allergy. 1998 Oct;53(10):969-75. doi: 10.1111/j.1398-9995.1998.tb03798.x.
Mizolastine is a new, nonsedating antihistamine with additional anti-inflammatory properties, providing relief in allergic rhinitis and urticaria. The aim of this study was to determine the efficacy and safety of 10 mg o.d. mizolastine given to patients with perennial allergic rhinoconjunctivitis.
This double-blind, placebo-controlled study involved 257 patients suffering from the disease for more than 10 years. They were allocated, after a 1-week placebo run-in, to receive mizolastine (n = 133) or placebo (n = 124) for 4 weeks.
Mizolastine-treated patients showed significantly greater alleviation of nasal symptoms, with a mean decrease of 36% compared with pretreatment score, compared to a mean decrease of 10% in placebo patients (P < 0.001). Nasal blockade responded favorably to mizolastine compared to placebo and was associated with a significant reduction in rhinoscopy findings (P = 0.030). Likewise, the mean ocular symptom score decreased 40% in mizolastine-treated patients compared to 7% in the placebo group (P < 0.003). The safety profile of mizolastine was satisfactory and similar to that of placebo.
In patients suffering from perennial allergic rhinoconjunctivitis, mizolastine is a safe and potent treatment. Mizolastine's pronounced effect on nasal blockade could possibly be linked to its anti-inflammatory properties.
咪唑斯汀是一种新型、无镇静作用且具有额外抗炎特性的抗组胺药，可缓解过敏性鼻炎和荨麻疹症状。本研究旨在确定每日口服10毫克咪唑斯汀治疗常年性变应性鼻结膜炎患者的疗效和安全性。
这项双盲、安慰剂对照研究纳入了257名患病超过10年的患者。在为期1周的安慰剂导入期后，他们被分配接受咪唑斯汀治疗（n = 133）或安慰剂治疗（n = 124），为期4周。
与安慰剂组患者相比，接受咪唑斯汀治疗的患者鼻症状缓解更为显著，与治疗前评分相比平均降低了36%，而安慰剂组患者平均降低了10%（P < 0.001）。与安慰剂相比，咪唑斯汀对鼻阻塞的治疗效果良好，并且鼻镜检查结果显著改善（P = 0.030）。同样，接受咪唑斯汀治疗的患者眼部症状评分平均降低了40%，而安慰剂组为7%（P < 0.003）。咪唑斯汀的安全性良好，与安慰剂相似。
对于常年性变应性鼻结膜炎患者，咪唑斯汀是一种安全有效的治疗药物。咪唑斯汀对鼻阻塞的显著疗效可能与其抗炎特性有关。
